Aspirin and Preeclampsia

Description

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Conditions

Preeclampsia Postpartum

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Aspirin to Prevent Cardiac Dysfunction in Preeclampsia

Aspirin and Preeclampsia

Condition
Preeclampsia Postpartum
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago Hospital, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Pregnant Adults between 18 and 45 years of age
  • 2. Diagnosed with preeclampsia
  • 3. Presenting for delivery with a singleton gestation.
  • 1. We will exclude patients in labor
  • 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
  • 3. Plan to deliver outside of the participating site
  • 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
  • 5. Aspirin allergy
  • 6. Clear indication for aspirin therapy or contraindication to aspirin therapy
  • 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
  • 8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
  • 9. Those who cannot provide consent

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Study Record Dates

2025-12-31